<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 10, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/5024881/global-induced-pluripotent-stem-cell-ipsc?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=93wv5g&amp;utm_campaign=2324009+-+Induced+Pluripotent+Stem+Cell+(iPSC)+Market+Size%2c+Trends+%26+Forecasts+2026-2034+by+Application%2c+Technology%2c+Cell+Type+and+Region&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, &amp; Forecasts, 2026">"Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, &amp; Forecasts, 2026"</a> has been added to ResearchAndMarkets.com's offering. Global Induced Pluripotent Stem Cell Market Advances Through Clinical Innovation, Investment and Commercial Expansion The global induced pluripotent stem cell (iPSC) market continues to expand as advances in regenerative medicine, cell and gene therapy, drug discovery and disease modeling accelerate commercial adoption. Since iPSC technology emerged in 2006, researchers and biotechnology companies have identified new disease mechanisms, developed more relevant drug-screening platforms and advanced iPSC-derived cell therapies into human clinical trials. Commercial applications for induced pluripotent stem cells now span therapeutic development, research services and industrial biotechnology. Key areas include: <ul><li>Cell Therapy: iPSC-derived cells are being evaluated as potential treatments for retinal diseases, neurodegenerative disorders, immune conditions, heart failure, diabetes and cancer.</li><li>Disease Modeling: Patient-derived iPSCs support the development of disease-specific cellular models for studying pathology and evaluating therapeutic candidates.</li><li>Drug Discovery and Development: iPSC-derived cells are used in target validation, compound screening, lead optimization and preclinical research.</li><li>Personalized Medicine and Gene Editing: The integration of iPSCs with CRISPR and other genome-editing platforms enables precise genetic modification and patient-specific therapeutic research.</li><li>Toxicology Testing: Human iPSC-derived cells provide relevant systems for assessing drug safety, toxicity and efficacy while supporting efforts to reduce animal testing.</li><li>Tissue Engineering, Organoids and 3D Bioprinting: iPSCs are used to develop engineered tissues, organoids and specialized bioinks for biomedical research and transplantation programs.</li><li>Research Tools and Stem Cell Banking: Commercial repositories and research suppliers provide standardized iPSC lines, differentiated cells, culture systems and related services.</li><li>Cultivated Meat: iPSC platforms are also being explored as scalable cell sources for sustainable food production.</li></ul> iPSC Market Dynamics The induced pluripotent stem cell sector has progressed rapidly from laboratory research to clinical evaluation. The first transplantation of an iPSC-derived cell product took place in Japan in 2013, only seven years after the technology was introduced. Led by Dr. Masayo Takahashi at the RIKEN Center in Kobe, the study evaluated iPSC-derived retinal tissue in patients with macular degeneration. In 2016, Cynata Therapeutics received approval to initiate a clinical trial of CYP-001, an allogeneic iPSC-derived mesenchymal stem cell product for steroid-resistant acute graft-versus-host disease. The program subsequently reported positive safety and efficacy results and met its clinical endpoints, supporting broader interest in scalable, allogeneic iPSC therapies. At least 228 clinical trials now involve iPSC technology, including 66 trials evaluating iPSC-derived cells as therapeutic products. Most therapeutic studies remain in Phase I or Phase II and address conditions such as Parkinson's disease, retinal disorders, heart failure, immune diseases and Type 1 diabetes. Investigational products include dopaminergic progenitors, retinal pigment epithelial cells, insulin-secreting beta cells, mesenchymal stem cells and iPSC-derived natural killer cells for cancer immunotherapy. Investment and consolidation are also shaping the iPSC market. Recent transactions include Axol Bioscience's acquisitions of Newcells Biotech and Phenocell, as well as Century Therapeutics' $35 million acquisition of Clade Therapeutics. Strategic partnerships and licensing agreements increasingly focus on good manufacturing practice-compliant production, automation, quality control and off-the-shelf allogeneic cell therapies. Venture capital investment in the sector totaled approximately $1.04 billion between 2023 and April 2026, compared with a peak of $2.15 billion in 2021. Funding has increasingly favored companies with proprietary manufacturing platforms, differentiated intellectual property and clear pathways from research products to clinical-stage therapeutics. Competitive Landscape FUJIFILM Cellular Dynamics International remains a major participant in the global iPSC industry. Cellular Dynamics International, founded in 2004 by Dr. James Thomson, became an early developer of human iPSC lines. FUJIFILM acquired the company for $307 million in 2015, creating a large-scale supplier of human iPSC-derived cells for research, drug development and regenerative medicine. ReproCELL was among the first companies to commercialize iPSC products, including its ReproCardio cardiomyocyte portfolio. European market participants include Evotec, which has developed an industrialized iPSC drug-discovery platform, and Ncardia, which specializes in cardiac and neural cell applications. Major life sciences suppliers, including Lonza, BD Biosciences, Thermo Fisher Scientific, Merck and Takara Bio, also contribute to the commercialization of iPSC-derived products, manufacturing technologies and research workflows. More than 90 companies are active across the broader induced pluripotent stem cell market, serving research, pharmaceutical and therapeutic customers. Global iPSC Market Report Scope The global iPSC market report examines the companies, technologies, partnerships and clinical programs influencing industry growth. Coverage includes iPSC research, cell manufacturing, patents, scientific publications, clinical trials, fundraising, initial public offerings, mergers and acquisitions, licensing transactions and co-development agreements. The report also analyzes the growing use of iPSCs in drug discovery, toxicology, disease modeling and regenerative medicine. Market estimates and forecasts through 2034 are segmented by application, technology, cell type and geography, including North America, Europe, Asia-Pacific and the rest of the world. Continued progress in scalable manufacturing, cell differentiation, genome editing and clinical development is expected to strengthen the commercial outlook for induced pluripotent stem cells. As therapeutic programs mature and research applications broaden, iPSC technology is positioned to play an increasingly important role in precision medicine, pharmaceutical development and next-generation cell therapies. Key Topics Covered 1. Report Overview 2. Introduction 3. Current Status of iPSC Industry 4. iPSC Manufacturing 5. Research Publications on Induced Pluripotent Stem Cells 6. iPSC Patent Landscape 7. Clinical Trial Landscape: Induced Pluripotent Stem Cells 8. M&amp;A, Collaborations and Funding Activities in iPSC Sector 9. Generation of Induced Pluripotent Stem Cells (iPSCs) 10. Human iPSC Banking 11. Biomedical Applications of iPSCs 12. Market Analysis 13. Company Profiles Companies Featured <ul><li>28bio</li><li>AcceGen</li><li>Accellta, Ltd.</li><li>Alder Therapeutics</li><li>Aldevron</li><li>Allele Biotechnology</li><li>Altos Labs</li><li>Applied StemCell, Inc. (ASC)</li><li>Arktus Therapeutics, Co., Ltd.</li><li>Aspen Neuroscience</li><li>ATCC</li><li>Axol Bioscience</li><li>Axxam S.p.A</li><li>BD Biosciences</li><li>Bit.bio</li><li>BlueRock Therapeutics</li><li>BPS Bioscience</li><li>BrainXell</li><li>BrainZell</li><li>BrightPath Biotherapeutics Co., Ltd.</li><li>Cartherics Pty Ltd</li><li>Catalent, Inc.</li><li>Cellectis</li><li>CellGenix GmbH</li><li>Cellistic</li><li>CellSystems GmbH</li><li>Cellusion, Inc</li><li>Celogics</li><li>Celregen Therapeutics</li><li>Century Therapeutics</li><li>Citius Pharmaceuticals, Inc.</li><li>clock.bio</li><li>Creative Medical Technology Holdings, Inc.</li><li>CUORiPS, Inc</li><li>Curi Bio, Inc</li><li>Cynata Therapeutics</li><li>CytoMed Therapeutics Limited</li><li>Defined Bioscience, Inc</li><li>Editas Medicine</li><li>EditCo Bio, Inc</li><li>ErneXa Therapeutics</li><li>Esco Lifesciences</li><li>Evotec</li><li>Eyestem Research Pvt. Ltd</li><li>Factor Biosynthesis, Inc.</li><li>Fate Therapeutics, Inc</li><li>FUJIFILM Cellular Dynamics</li><li>Gameto, Inc</li><li>GC Therapeutics</li><li>GenScript</li><li>GOLIVER THERAPEUTICS</li><li>Greenstone Biosciences</li><li>Healios K.K</li><li>HeartBeat.bio AG</li><li>Heartseed, Inc.</li><li>Hebecell Corporation</li><li>HELP Therapeutics</li><li>Herophilus</li><li>Hesperos, Inc.</li><li>Horizon Discovery</li><li>HUB Organoids BV</li><li>iCamuno Biotherapeutics</li><li>iHeart Japan Corporation</li><li>IN8Bio</li><li>InSphero</li><li>iPeace, Inc</li><li>iPS Academia Japan, Inc.</li><li>IPS HEART</li><li>iPSirius</li><li>iRegene Therapeutics</li><li>iXCells Biotechnologies</li><li>iXgene, Inc</li><li>Jacobio Pharmaceuticals</li><li>Kangstem Biotech</li><li>Kenai Therapeutics</li><li>Khloris Biosciences, Inc.</li><li>Kiji Therapeutics</li><li>Lambda Biologics GmbH</li><li>Laverock Therapeutics</li><li>Lineage Cell Therapeutics</li><li>Lonza</li><li>Megakaryon Corporation</li><li>Miltenyi Biotec, Inc.</li><li>Morphocell Technologies, Inc</li><li>Myoridge Co. Ltd.</li><li>Ncardia</li><li>NeuCyte, Inc</li><li>Neukio Biotherapeutics</li><li>NEXEL</li><li>Okomera</li><li>Organovo Holdings, Inc</li><li>Orizuru Therapeutics</li><li>Oxford StemTech</li><li>Parallel Bio</li><li>Pixl Bio, Ltd</li><li>Pluristyx, Inc.</li><li>Porosome Therapeutics, Inc.</li><li>Quell Therapeutics Ltd</li><li>Racthera Co., Ltd.</li><li>Rege Nephro, Co., Ltd.</li><li>Repairon GmbH</li><li>ReproCELL</li><li>Res Nova Biologics</li><li>Ricoh Biosciences, Inc.</li><li>Sampled</li><li>Sana Biotechnology</li><li>Sarcio, Inc</li><li>SCG Cell Therapy, Pte. Ltd</li><li>SereNeuro Therapeutics</li><li>Shinobi Therapeutics</li><li>StemCardia</li><li>STEMCELL Technologies</li><li>StemSight</li><li>Stemson Therapeutics</li><li>Stimuliver</li><li>Sumitomo Pharma</li><li>Synthego</li><li>Telescope Therapeutics</li><li>Tempo Bioscience</li><li>Tenaya Therapeutics</li><li>TGD Life Company Limited</li><li>Thermo Fisher Scientific Inc</li><li>Tolerance Bio</li><li>Trailhead Biosystems</li><li>TreeFrog Therapeutics</li><li>Vanqua Bio</li><li>Vascugen, Inc</li><li>VCCT Inc</li><li>Vertex Pharmaceuticals</li><li>Vivodyne</li><li>Yashraj Biotechnology, Ltd</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5024881/global-induced-pluripotent-stem-cell-ipsc?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=93wv5g&amp;utm_campaign=2324009+-+Induced+Pluripotent+Stem+Cell+(iPSC)+Market+Size%2c+Trends+%26+Forecasts+2026-2034+by+Application%2c+Technology%2c+Cell+Type+and+Region&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/vx71rh</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ODg0OTRiZGYtN2JhYi00NGQ1LWEzNzgtYjkzMzE0YjQ5OWU4LTEwMjY3MzctMjAyNi0wOC0xMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Induced Pluripotent Stem Cell (iPSC) Market Size, Trends & Forecasts 2026-2034 by Application, Technology, Cell Type and Region

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn